期刊文献+

肾移植术后华法林不敏感患者的用药分析 被引量:1

Analysis of one case of warfarin-insensitive in a patient with kidney transplantation
原文传递
导出
摘要 目的探讨临床药师在华法林不敏感患者个体化抗凝治疗中的作用。方法通过参与1例肾移植患者进行人工血管旁路移植术后使用华法林不敏感的抗凝治疗过程,分析该患者华法林不敏感的原因,参与药物治疗方案调整,对患者进行药学监护。结果患者同时服用的硫唑嘌呤、环孢素软胶囊和基因型(CYP2C9*1/*1和VKORC1-1639GA)是减弱华法林作用的主要因素。结论结合患者合并用药和基因型监测等因素为患者提供华法林个体化抗凝治疗,提高抗凝治疗的有效性和安全性。 Objective To explore the role of clinical pharmacists in individualized anticoagulant therapy in the patients who were insensitive to warfarin.Mehtods Through clinical pharmacists’participation in anticoagulation therapy of one prosthetic vessel bypass grafting patient after kidney transplantation,the reason for warfarin insensitivity was analyzed,the causes of warfarin insensitivity in this patient were analyzed,the adjustment of drug treatment scheme was involved,and the patients were monitored pharmacologically.Results The patient’s medications such as azathioprine and ciclosporin and genotype results(CYP2 C9*1/*1 and VKORC1-1639 GA)may be the reason of warfarin insensitivity.Conclusion Medications and genotype testing could provide patients with individualized warfarin anticoagulation and improve the effectiveness and safety of anticoagulant therapy.
作者 刘秀梅 都丽萍 梅丹 LIU Xiu-mei;DU Li-ping;MEI Dan(Department of Pharmacy,People’s Hospital of Zhengzhou,Zhengzhou 450003,Henan Province,China;Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2019年第10期1042-1043,1048,共3页 The Chinese Journal of Clinical Pharmacology
基金 首都卫生发展科研专项基金资助项目(首发2018-3-4017) 中国医学科学院医学与健康科技创新工程项目基金资助项目(2017-I2M-1-011)
关键词 华法林不敏感 药物相互作用 基因型 warfarin insensitive drug interaction genotype
  • 相关文献

参考文献3

二级参考文献19

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献762

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部